Retina Today Journal Club moderator Richard Kaiser, MD, sat down with Baruch Kuppermann, MD, Professor of Ophthalmology and Biomedical Engineering, Chief, Retina Service, and Vice-Chair, Clinical Research, Ophthalmology at the University of California Irvine to discuss the paper he presented on post-vitrectomy outcomes when treating patients with ocriplasmin (Jetrea, Thrombogenics).
The discussion starts with the topline results showing a 26.5% benefit to patients with vitreomacular adhesion (VMA) or small macular holes, compared to just 10% in the placebo injection group. Drs. Kaiser and Kupperman conclude that there is no harm in using ocriplasmin to treat VMA and macular holes, however it is important to evaluate patients to determine their best course of treatment.
ThromboGenics • Vitrectomy